Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it willfeature handheld robotics and digital solutions for hip, knee and shoulder in addition toinnovative trauma and extremities products during the American Academy of Orthopaedic Surgeons(AAOS) Annual Meeting in New Orleans this week. Some of the company’s latest Orthopaedicsadvancements and highlighted technologies include:Handheld Robotics:Optimizing and Personalizing Surgery

As the leader in handheld robotics, the CORI◊Surgical System delivers a digital surgeryecosystem–spanning solutions from advanced pre-operative planning and a connected post-operativedata management solution. The entire robotics ecosystem is designed to amplify the surgeonexperience and expertise and has shown improvements in accuracy and patient outcomes in joint arthroplasty.¹,²

Smith+Nephew’s CORIOGRAPH◊Pre-Op Planning and Modeling Services enables optimization of handheldrobotic knee and shoulder* arthroplasty and computer guided hip – further personalizing surgery forboth surgeons and their patients. CORIOGRAPH Pre-Op Planning and Modeling Services + CORI SurgicalSystem supports several image modalities - allowing for a new dimension of pre-operative planningfor each individual patient - and supporting the intra-operative surgical workflow.In the booth at AAOS, Smith+Nephew will have a motion capture lounge demonstrating how 3-D modelingof patient motion is important in planning implant position and advanced simulated activities ofdaily living.*CORI XT is required for shoulder application

In the fast-growing shoulder market, the CORI SHOULDER Platform is well positioned to meet the unmetneeds of surgeons who demand both accuracy and procedural efficiency. The system is specificallyoptimized for use with the AETOS Shoulder System. It features the CORI Handheld Robotic Platformtechnology and supports robotic preparation of both humeral and glenoid execution for shoulderarthroplasty.

Smith+Nephew advances robotic shoulder arthroplasty with a complete, handheld solution thatsupports seamless integration and workflow efficiencies for shoulder arthroplasty.³ The procedurerepresents a significant leap forward in the shoulder arthroplasty space, perfectly suited for theconstraints of the anatomy and supported by a portable footprint for flexibility in the hospital orASC.Last week, the first ever CORI SHOULDER Robotic Shoulder Arthroplasty cases were completed,performed by a surgical team at Duke Health led by Dr. Christopher Klifto. To learn more, pleasevisit the CORI SHOULDER website or see a live demo of CORI SHOULDER Robotic Shoulder Arthroplastyat AAOS in Booth #839.Advanced Implant ScienceGet the latest clinical data and insights on our flagship implant options for hip, knee andshoulder arthroplasty including recent additions to our portfolio such as LEGION◊Total Knee MedialStabilized System, CATALYSTEM◊Primary Hip System and the AETOS Shoulder System stemless option.

Trauma AdvancementsFrom reduction to fixation, the EVOS◊LARGE & PERIPROSTHETIC Plating System has evolved to givesurgeons stability and flexibility with one screw design for threaded locking, and variable-anglelocking and compatibility with the EVOS Cabling System. We will also be expanding the EVOSportfolio this year with the launch of the EVOS PELVIC System.TRIGEN◊MAX Tibia Nailing System is the only system to give trauma surgeons the choice ofside-specific (right and left) nails for anatomic screw trajectories, which help to optimizefragment fixation and minimize soft tissue irritation with headless and low-profile screwoptions.⁴,⁵ Come visitSmith+Nephew at Booth #839and hear about the expansion of TRIGEN MAX Tibiathis year.Smith+Nephew has also recently signed distribution agreements withSI-BONE, focused on theirinnovative iFuse TORQ portfoliofor pelvic fractures andRMR Ortho for the A’TOMIC™ NitinolFixation System, a compression fixation option for trauma cases.

At the ASC suite, Smith+Nephew will provide customers with a preview of our expanded enterprise ASCoffering—an end-to-end solution designed to support both de novo ASC development and themodernization of existing facilities. This comprehensive model enables customers to finance,design, build, equip, and optimize their centers through one coordinated, streamlined pathway.Through new strategic partnerships with Brasfield & Gorrie, Ghafari Associates, Unity HealthCenters, and STERIS, we are bringing best-in-class expertise and technologies together into asingle, aligned delivery model—helping customers accelerate timelines, reduce complexity, and driveoperational performance from day one.To learn more about Smith+Nephew’s advanced solutions for orthopaedic reconstruction, please visitBooth #839 at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans, LAMarch 3-6, 2026 or visitwww.smith-nephew.com

- ends –

References:1. Bollars P, Janssen D, De Weerdt W, et al. Improved accuracy of implant placement with animageless handheld robotic system compared to conventional instrumentation in patients undergoingtotal knee arthroplasty: a prospective randomized controlled trial using CT-based assessment ofradiological outcomes. Knee Surg Sports Traumatol Arthrosc. 2023;31(12):5446-5452.2. Bollars P, Nathwani D, Albelooshi A, et al. Imageless handheld robotic-assisted total kneearthroplasty showed better clinical outcomes than conventional total knee arthroplasty: Arandomized controlled trial with preliminary results at 1-year follow up. Knee.2025;56(10):232-240.3. Smith+Nephew 2025. Internal Report. 101581294. Smith+Nephew 2023. Internal Report 10092864 Ver A.7. I20-4GEN-A Verification Activity - TRIGENMAX Tibial Nail5. Smith+Nephew 2023. Internal Report 10092852 Ver A. I20-4GEN-A Verification Activity - ScrewProminence]Media EnquiriesGina Kamler+1 (901) 262-9070Smith+Nephewgina.kamler@smith-nephew.comAbout Smith+NephewSmith+Nephew is a portfolio medical technology business focused on the repair, regeneration andreplacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief byusing technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000employees deliver this mission every day, making a difference to patients’ lives through theexcellence of our product portfolio, and the invention and application of new technologies acrossour three global business units of Orthopaedics, Sports Medicine & ENT and Advanced WoundManagement.Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of$6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidatedsubsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visitwww.smith-nephew.comand follow us on X,LinkedIn, Instagram or Facebook. For more information about Smith+Nephew, please visitwww.smith-nephew.comand follow us on LinkedIn, Instagram or Facebook.

Forward-looking StatementsThis document may contain forward-looking statements that may or may not prove accurate. Forexample, statements regarding expected revenue growth and trading profit margins, market trends andour product pipeline are forward-looking statements.Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate","expect", "target", "consider" and similar expressions are generally intended to identifyforward-looking statements. Forward-looking statements involve known and unknown risks,uncertainties and other important factors that could cause actual results to differ materially fromwhat is expressed or implied by the statements. For Smith+Nephew, these factors include: conflictsin Europe and the Middle East, economic and financial conditions in the markets we serve,especially those affecting healthcare providers, payers and customers; price levels for establishedand innovative medical devices; developments in medical technology; regulatory approvals,reimbursement decisions or other government actions; product defects or recalls or other problemswith quality management systems or failure to comply with related regulations; litigation relatingto patent or other claims; legal and financial compliance risks and related investigative, remedialor enforcement actions; disruption to our supply chain or operations or those of our suppliers;competition for qualified personnel; strategic actions, including acquisitions and disposals, oursuccess in performing due diligence, valuing and integrating acquired businesses; disruption thatmay result from transactions or other changes we make in our business plans or organisation toadapt to market developments; relationships with healthcare professionals; reliance on informationtechnology and cybersecurity; disruptions due to natural disasters, weather and climate changerelated events; changes in customer and other stakeholder sustainability expectations; changes intaxation regulations; effects of foreign exchange volatility; and numerous other matters thataffect us or our markets, including those of a political, economic, business, competitive orreputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S.Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended,including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’swebsite at www. sec.gov, for a discussion of certain of these factors. Any forward-lookingstatement is based on information available to Smith+Nephew as of the date of the statement. Allwritten or oral forward-looking statements attributable to Smith+Nephew are qualified by thiscaution. Smith+Nephew does not undertake any obligation to update or revise any forward-lookingstatement to reflect any change in circumstances or in Smith+Nephew's expectations.◊Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.